STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 June 2002 please refer to module 8B.  
• 
• 
• 
• 
• 
-  
-  
-  
-  
• 
On 8 January 1999, the Marketing Authorisation Holder submitted to the EMEA an application 
for Micardis 20 mg tablets, under Annex II to Commission Regulation (EC) 542/95 as amended. 
The CPMP recommended the approval for this additional strength and adopted an opinion on 20 
May 1999. The respective Commission Decision was issued on 7 September 1999. 
Pursuant to Article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992, the Marketing 
Authorisation  Holder, notified the EMEA on 26  February 1999 of their intention to introduce 
changes to an aspect of the labelling not connected to the Summary of Product Characteristics. 
The  Company  requested  additional  changes  on  8  March  and  27  April  1999.  (Changes  to  the 
Austrian contact address and the Danish contact fax number have been introduced. The section 
“Storage conditions” of the package leaflet has been amended in order to be consistent with the 
section  “Special  precautions  for  storage”  of  the  SPC.  Linguistic  corrections  have  been 
implemented into the German and Greek package leaflet.). On 30 April 1999, the EMEA hereby 
informs  the  European  Commission  that  the  above-mentioned  changes  are  accepted.  The 
respective Commission Decision was issued on 03 June 1999. 
The Marketing Authorisation Holder submitted to the EMEA on 8 March 1999 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No.  15  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
Several  minor  changes  to  the  manufacturing  process  of  the  finished  product,  including  an 
increase in batch size. 
On  19  April  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require 
amendments to the Commission Decision. 
The Marketing Authorisation Holder submitted to the EMEA on 8 March 1999 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No.  1  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
A change in the sites of the manufacture of spray dried granulates. 
On  19  April  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require 
amendments to the Commission Decision. 
The Marketing Authorisation Holder submitted to the EMEA, between 6 September 1999 and 
19 November 1999, a number of applications for one type I variation falling within the scopes 
of item No 1, 12a, 14, 24a and 32 of Annex I to Commission Regulation (EC) No 542/95, as 
amended. The Marketing Authorisation Holder applied for: 
Change  of  the  manufacturing  sites  for  part  of  the  manufacturing  process  of  the  medicinal 
product, 
Change of imprints, bossing or other markings (except scoring) on tablets. 
Change  in  specification  of  starting  material  or  intermediate  used  in  the  manufacture  of  the 
active substance (with Change in specification of active substance). 
Changes  in  test procedure  for starting material or intermediate used in the manufacture of the 
active substance. 
Between  29  October  1999  and  15  March  2000,  the  EMEA  issued  the  corresponding 
notifications. These variations did not require amendments to the Commission Decision. 
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  8  November  1999  an 
application  for  one  type  I  variation  falling  within  the  scope  of  item  No  20  of  Annex  I  to 
Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder 
applied for: 
1/2 
                   EMEA 2005 
 
 
 
 
 
 
 
• 
• 
An extension of shelf-life. 
On 17 December 1999, the EMEA issued the corresponding notification. The variation required 
amendments  in the relevant sections of the Commission  decision. The respective Commission 
Decision was issued on 09 March 2000. 
Pursuant to Article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992, the Marketing 
Authorisation  Holder,  notified  the  EMEA  on  9  February  2000  of  their  intention  to  introduce 
changes  to  an  aspect  of  the  labelling  of  the  20  mg  strength  not  connected  to  the  Summary  of 
Product  Characteristics.  Changes  were  related  to  the  list  of  Marketing  Authorisation 
representatives  or  were  of  linguistic  nature.  On  21  February  2000,  the  EMEA  issued  the 
corresponding notification. The respective Commission Decision was issued on  
30 March 2000. 
On  31  January  2000,  the  Marketing  Authorisation  Holder  submitted  a  Type  II  variation 
application in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of  
10 March 1995, as amended. The scope of the variation related to the update of the SPC and PL 
of the 40 and 80 mg strengths to put them in line with the SPC and PL of the recently approved 
20 mg strength and with the latest QRD SPC/labelling/PL templates. In addition, the list of local 
representatives of the Marketing Authorisation Holder in the Package Leaflet has been updated. 
During  the  assessment,  sections  on  pregnancy  and  interaction  with  food  have  been  revised  in 
order to be more accurate. 
On 12 April 2000, the CPMP approved the variation. The variation required amendments in the 
relevant  sections  of  the  Commission  Decision  and  the  EPAR.  The  European  Commission 
amended the Decision on 1 August 2000. 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Minor change of manufacturing process of the active substance 
With consequential change in test procedure for starting 
material/intermediate used in manuf. of active substance 
Batch size of active substance 
Change in test procedures of the medicinal product 
Changes in manufacture of the medicinal product 
Update of Summary of Product Characteristics and Package Leaflet 
The SPC was updated following the assessment of the 2nd and 3rd 
PSUR.  
Replacement of an excipient with a comparable excipient 
Extension of shelf-life as foreseen at time of authorisation 
Change in pack size for a medicinal product 
Update of Summary of Product Characteristics and Package Leaflet 
Change in the name of a manufacturer of the medicinal product 
I/0016 
I/0017 
I/0018 
I/0019 
II/0020 
I/0021 
I/0022 
I/0023 
II/0024 
I/0026 
I 
I 
I 
I 
II 
I 
I 
I 
II 
I 
Notification/ 
Opinion 
issued on2 
02.08.00 
Commission 
Decision 
Issued/amended 
on 
N/A 
02.08.00 
15.08.00 
22.09.00 
N/A 
N/A 
N/A 
19.10.00 
22.01.01 
04.05.01 
22.08.01 
23.08.01 
21.02.02 
23.05.02 
- 
19.10.01 
19.10.01 
30.05.02 
24.05.02 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
2/2 
                   EMEA 2005 
 
 
 
 
 
 
 
 
 
                                                            
 
